Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored Prednisone Reduction Versus Usual Care for Hyperglycemia During R-CHOP Chemotherapy
NCT03505762Phase 2Active, not recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2018
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of prednisone in hyperglycemia (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Cumulative Percentage of Patients With Hyperglycemia at 63 days. Started Jul 2018; status: active, not recruiting.
02
Drugs
prednisone
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT03505762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505762.